JPH0113691B2 - - Google Patents
Info
- Publication number
- JPH0113691B2 JPH0113691B2 JP60013608A JP1360885A JPH0113691B2 JP H0113691 B2 JPH0113691 B2 JP H0113691B2 JP 60013608 A JP60013608 A JP 60013608A JP 1360885 A JP1360885 A JP 1360885A JP H0113691 B2 JPH0113691 B2 JP H0113691B2
- Authority
- JP
- Japan
- Prior art keywords
- calcium
- electrolytic
- weight
- parts
- ionized calcium
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired
Links
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 claims description 37
- 239000011575 calcium Substances 0.000 claims description 37
- 229910052791 calcium Inorganic materials 0.000 claims description 37
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 claims description 27
- 238000002360 preparation method Methods 0.000 claims description 15
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 claims description 12
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 claims description 12
- 239000000203 mixture Substances 0.000 claims description 4
- GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 claims description 3
- 210000002784 stomach Anatomy 0.000 description 15
- 230000007794 irritation Effects 0.000 description 5
- 229910052500 inorganic mineral Inorganic materials 0.000 description 3
- 235000012054 meals Nutrition 0.000 description 3
- 239000011707 mineral Substances 0.000 description 3
- 238000002156 mixing Methods 0.000 description 3
- 238000006386 neutralization reaction Methods 0.000 description 3
- 206010047700 Vomiting Diseases 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 230000002378 acidificating effect Effects 0.000 description 2
- 235000015872 dietary supplement Nutrition 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 230000031891 intestinal absorption Effects 0.000 description 2
- 238000000034 method Methods 0.000 description 2
- 230000008673 vomiting Effects 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- 206010000087 Abdominal pain upper Diseases 0.000 description 1
- 241000251468 Actinopterygii Species 0.000 description 1
- 241001474374 Blennius Species 0.000 description 1
- 206010006956 Calcium deficiency Diseases 0.000 description 1
- 206010028813 Nausea Diseases 0.000 description 1
- 241000237502 Ostreidae Species 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 230000006735 deficit Effects 0.000 description 1
- 239000003792 electrolyte Substances 0.000 description 1
- 210000001156 gastric mucosa Anatomy 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 239000008239 natural water Substances 0.000 description 1
- 230000008693 nausea Effects 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 235000020636 oyster Nutrition 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 239000002689 soil Substances 0.000 description 1
- 230000009469 supplementation Effects 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
Landscapes
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Description
【発明の詳細な説明】
（産業上の利用分野）
本発明は、経口電解ボレイイオン化カルシウム
製剤に関するものであり、より詳細には空腹時の
服用においても、胃の粘膜に対する刺激性、不快
感をなくした経口電解ボレイイオン化カルシウム
製剤に関する。Detailed Description of the Invention (Industrial Application Field) The present invention relates to an oral electrolytic boley ionized calcium preparation, and more specifically, it does not cause irritation or discomfort to the gastric mucosa even when taken on an empty stomach. Regarding the lost oral electrolytic Borei ionized calcium preparation.
（従来の技術及びその問題点）
カルシウムが丈夫が骨や歯をつくるために栄養
素としただけでなく、血液の浄化や、脳、神経、
心臓、筋肉など人間の生命を維持してゆく上で、
極めて重要な働きを担つていることが最近の研究
で次々と明らかにされている。(Conventional technology and its problems) Calcium is not only used as a nutrient for building strong bones and teeth, but also for blood purification, the brain, nerves, etc.
In maintaining human life, such as the heart and muscles,
Recent research has revealed that it plays an extremely important role.
とくに、成人病といわれる病気の殆んどがカル
シウムなどのミネラル不足が原因であると多くの
学者が指摘しているし、厚生省の調査によつても
今日の国民の半健康状態がカルシウム不足に基因
するものであることが指摘されている。 In particular, many scholars have pointed out that most of the so-called adult diseases are caused by a lack of minerals such as calcium, and a survey by the Ministry of Health and Welfare has also shown that the semi-healthy state of today's people is due to a lack of calcium. It has been pointed out that this is the underlying cause.
人間の主なカルシウム補給源は、本来、通常の
食事に工夫をこらして摂取することが理想である
が、魚、野菜、海藻などをどんなに豊富に食事に
摂り入れても、一日のカルシウム必要量である
600〜700mgには遠く及ばないものであり、それを
補うために牛乳やミネラル分を豊富に含む自然の
水を服用することが行われている。しかしなが
ら、日本の水は日本の国土全体が火山土質である
ため、ヨーロツパの水にくらべると、カルシウム
分は1/5程度の含有量しかない。 Ideally, the main source of calcium supplementation for humans should be ingested through regular meals, but no matter how richly fish, vegetables, seaweed, etc. is the amount
This is far from 600 to 700 mg, and to compensate for this, people are taking milk and natural water rich in minerals. However, since Japan's entire land is made of volcanic soil, Japan's water contains only about 1/5 of the calcium content of European water.
従つて、日本人は慢性的なカルシウム不足に陥
り、先に述べたような各機能に障害をもたらすこ
とになる。 Therefore, Japanese people suffer from chronic calcium deficiency, which leads to impairments in the various functions mentioned above.
そこで、この半健康状態を改善するために、栄
養補助食品としてのカルシウム製剤が市場に進出
するようになつた。ところが、カルシウム製剤は
体内での吸収が良くなく、最近は吸収性を向上さ
せるための研究が盛んに行われるようになりいく
つかの成果も発表されている。その主なものとし
てはカルシウムをイオン化することによつて、高
濃度のイオン化濃度を付与するものである。 Therefore, in order to improve this semi-healthy condition, calcium preparations as nutritional supplements have entered the market. However, calcium preparations are not well absorbed in the body, and recently, research has been actively conducted to improve absorption, and some results have been published. The main method is to impart a high ionization concentration by ionizing calcium.
とくに本発明者らが開発した電解ボレイは、牡
蛎殻を電解精製したもので、ミネラルを多量に含
み超高濃度のイオン化濃度を示すものであり、腸
内での吸収が抜群にすぐれているという特徴があ
る。この電解ボレイイオン化カルシウムは財団法
人日本食品分析センターによる電気伝導率の測定
によると、イオン化濃度が10000μs／cm（25℃）
という超高濃度のイオン化濃度を示し、市販のカ
ルシウム製剤の81〜790μs／cm（25℃）というイ
オン化濃度に比較して極めて高い測定値を示すも
のであり、そのすぐれた腸内吸収性が評価され、
現在も各大学の付属病院をはじめとする医療機関
において、積極的に成人病の予防、治療のための
栄養補助食品として採用されている。 In particular, the electrolytic borei developed by the present inventors is made from electrolytically refined oyster shells, contains large amounts of minerals, exhibits an ultra-high ionization concentration, and is said to be extremely well absorbed in the intestines. It has characteristics. According to the measurement of the electrical conductivity of this electrolyzed Borei ionized calcium by the Japan Food Research Center, the ionization concentration is 10000μs/cm (25℃).
It exhibits an extremely high ionization concentration, which is extremely high compared to the ionization concentration of commercially available calcium preparations of 81 to 790μs/cm (25℃), and its excellent intestinal absorption has been evaluated. is,
Currently, it is actively used as a nutritional supplement for the prevention and treatment of adult diseases in medical institutions such as university hospitals.
ところが、最近になつてカルシウムに関する研
究が進むにつれて、従来のように、食後に服用す
るだけでなく、もつと多量を数回にわたつて摂取
することが推奨されるようになつた。しかしなが
ら、胃弱者が電解ボレイイオン化カルシウムを空
腹時に服用すると、食後の服用においては殆ど問
題にならなかつた胃に対する刺激性や不快感を感
じるケースが見られ、人によつては嘔吐感を伴う
などの悪影響が問題となつてきた。 However, as research on calcium has progressed in recent years, it has become recommended not only to take it after meals, but also to take large amounts over several times. However, when people with sensitive stomachs take electrolyzed Borei ionized calcium on an empty stomach, there are cases where they feel irritation and discomfort to the stomach, which is rarely a problem when taken after meals, and some people may experience vomiting. The negative effects of this have become a problem.
（発明の目的）
そこで、本発明の目的は、腸内吸収性を低下さ
せることなく、胃弱者や空腹時の服用によつて
も、刺激性や不快感を感じることなくカルシウム
の摂取ができる電解ボレイイオン化カルシウム製
剤を提供することにある。(Objective of the Invention) Therefore, the object of the present invention is to provide an electrolytic electrolyte that allows calcium to be taken in without reducing intestinal absorption and without causing irritation or discomfort, even for people with a weak stomach or when taking it on an empty stomach. An object of the present invention is to provide a Borei ionized calcium preparation.
（問題点を解決するための手段）
本発明によれば、電解ボレイイオン化カルシウ
ムに、還元麦芽糖およびクエン酸の混合物を配合
したことを特徴とする経口電解ボレイイオン化カ
ルシウム製剤が提供される。(Means for Solving the Problems) According to the present invention, there is provided an oral electrolytic boley ionized calcium preparation characterized by blending electrolytic boley ionized calcium with a mixture of reduced maltose and citric acid.
（作用）
本発明者らの研究によれば、前記服用時の刺激
性や不快感は、電解ボレイイオン化カルシウムの
強アルカリ性に基因するものであることが判明し
た。(Effect) According to the research conducted by the present inventors, it has been found that the irritation and discomfort during administration are due to the strong alkalinity of electrolytic boley ionized calcium.
すなわち、PHが10以上という強アルカリ性を示
す電解ボレイイオン化カルシウムを空腹時に服用
すると、胃内で急激に溶け、ただちに胃内の酸と
急激な中和反応をひき起こし、胃内の酸性状態の
バランスを欠く結果、それが、胃壁への刺激性、
不快感を感じさせるもととなり、胃痛や嘔吐感と
なつて表われるものと推定される。 In other words, when electrolyzed boley ionized calcium, which has a pH of 10 or more and is strongly alkaline, is taken on an empty stomach, it rapidly dissolves in the stomach and immediately causes a rapid neutralization reaction with the acid in the stomach, causing an imbalance in the acidic state in the stomach. As a result, it is irritating to the stomach wall,
It is estimated that this causes discomfort, which manifests as stomach pain and vomiting.
そこで、本発明者らは電解ボレイイオン化カル
シウムのPHを予じめ、PH７〜９程度の中性乃至弱
酸性に調整しておくと同時に、胃内の酸との反応
を緩慢化することによつて、服用時に不快感を伴
わない電解ボレイイオン化カルシウム製剤がえら
れるであろうとの予想をもとに研究を進めた結
果、到達したのが本発明である。 Therefore, the present inventors adjusted the pH of electrolytic ionized calcium in advance to a neutral to slightly acidic pH of about 7 to 9, and at the same time slowed down the reaction with acid in the stomach. The present invention was developed as a result of research based on the expectation that an electrolytically ionized calcium preparation that would not cause discomfort upon administration would be available.
本発明におけるクエン酸は、電解ボレイイオン
化カルシウムのPHを調整するのに役立ち、さら
に、これと同時に還元麦芽糖を配合することによ
つて、カルシウム製剤の表面が還元麦芽糖によつ
て薄くコーテイングされ、胃内での中和反応の緩
慢化が達成される。電解ボレイイオン化カルシウ
ムに還元麦芽糖のみを配合した場合でも、カルシ
ウム製剤の還元麦芽糖によるコーテイングは達成
れ、胃内における中和反応の緩慢化は計かれる
が、服用時の不快感を全く解消するためにはクエ
ン酸と還元麦芽糖を併用することが望ましい。 The citric acid in the present invention is useful for adjusting the pH of electrolyzed boley ionized calcium, and by adding reduced maltose at the same time, the surface of the calcium preparation is thinly coated with reduced maltose, and the stomach Slowing down of the neutralization reaction within is achieved. Even when only reduced maltose is combined with electrolyzed Borei ionized calcium, coating of the calcium preparation with reduced maltose can be achieved and the neutralization reaction in the stomach can be slowed down, but it is difficult to completely eliminate the discomfort when taking it. It is desirable to use citric acid and reduced maltose together.
（好適態様の説明）
電解ボレイイオン化カルシウムに対する還元麦
芽糖とクエン酸の配合割合は、ほとんど厳密なも
のではないが目安としては、電解ボレイイオン化
カルシウム100重量部に対して、還元麦芽糖が50
乃至200重量部、好ましくは100乃至150重量部、
クエン酸が30乃至250重量部、好ましくは50乃至
200重量部の配合が推奨される。(Description of preferred embodiments) The blending ratio of reduced maltose and citric acid to electrolytic bolay ionized calcium is not very strict, but as a guideline, reduced maltose should be 50 parts by weight to 100 parts by weight of electrolytic boley ionized calcium.
from 100 to 200 parts by weight, preferably from 100 to 150 parts by weight,
30 to 250 parts by weight of citric acid, preferably 50 to 250 parts by weight
A formulation of 200 parts by weight is recommended.
本発明における上記各成分は、例えばいずれも
100乃至300メツシユ程度の微粉末の状態で混合さ
れ、自体公知の製剤方法によつて打錠されるもの
であるが、各成分の粒径をいずれも200メツシユ
程度で混合することにより好適な打錠が達成され
る。 Each of the above components in the present invention is, for example,
It is mixed in the form of a fine powder of about 100 to 300 mesh, and is compressed into tablets using a known formulation method. However, by mixing each component with a particle size of about 200 mesh, a suitable tablet can be obtained. The lock is achieved.
実施例 １
電解ボレイイオン化カルシウム 100重量部
還元麦芽糖 150重量部
クエン酸 50重量部
以上の成分を同時に配合し十分に混練後、自体
公知の打錠機にて、１粒が150mgのカルシウム製
剤を得た。Example 1 Electrolytic Borei Ionized Calcium 100 parts by weight Reduced maltose 150 parts by weight Citric acid 50 parts By weight, the above ingredients were mixed at the same time and thoroughly kneaded using a known tablet machine to obtain a calcium preparation containing 150 mg per tablet. Ta.
実施例 ２
電解ボレイイオン化カルシウム100重量部に対
して、還元麦芽糖を110重量部、クエン酸を160重
量部した以外は実施例１と同様にして、１粒が
150mgのカルシウム製剤を得た。Example 2 One grain was prepared in the same manner as in Example 1 except that 110 parts by weight of reduced maltose and 160 parts by weight of citric acid were added to 100 parts by weight of electrolyzed boley ionized calcium.
150 mg of calcium preparation was obtained.
以上の処方によりえられた電解ボレイイオン化
カルシウム製剤は、、いずれも空腹時の服用によ
つても、刺激性、不快感を感じることがなく、多
めに服用しても嘔吐感を伴うことがなかつた。 The electrolytic Borei ionized calcium preparations obtained from the above prescriptions do not cause irritation or discomfort even when taken on an empty stomach, and do not cause nausea even when taken in large quantities. Ta.
Claims (1)
糖およびクエン酸の混合物を配合したことを特徴
とする経口電解ボレイイオン化カルシウム製剤。 ２ 電解ボレイイオン化カルシウム100重量部に
対して還元麦芽糖50乃至200重量部およびクエン
酸30乃至250重量部を配合する特許請求の範囲第
１項記載の経口電解ボレイイオン化カルシウム製
剤。[Scope of Claims] 1. An oral electrolytic Borei ionized calcium preparation, characterized in that a mixture of reduced maltose and citric acid is blended with electrolytic Borei ionized calcium. 2. The oral electrolytic ionized calcium preparation according to claim 1, which contains 50 to 200 parts by weight of reduced maltose and 30 to 250 parts by weight of citric acid to 100 parts by weight of electrolytic ionized calcium.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP1360885A JPS61172822A (en) | 1985-01-29 | 1985-01-29 | Ionized calcium preparation for oral administration containing electrolyzed oyster shell |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP1360885A JPS61172822A (en) | 1985-01-29 | 1985-01-29 | Ionized calcium preparation for oral administration containing electrolyzed oyster shell |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JPS61172822A JPS61172822A (en) | 1986-08-04 |
| JPH0113691B2 true JPH0113691B2 (en) | 1989-03-07 |
Family
ID=11837941
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP1360885A Granted JPS61172822A (en) | 1985-01-29 | 1985-01-29 | Ionized calcium preparation for oral administration containing electrolyzed oyster shell |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JPS61172822A (en) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS62263126A (en) * | 1986-05-12 | 1987-11-16 | Fuji Kikaku:Kk | Ionized calcium preparation for oral administration produced from electrolyzed oyster shell |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS5148467A (en) * | 1974-10-23 | 1976-04-26 | Kyoko Ootsu | |
| JPS5585385A (en) * | 1978-12-22 | 1980-06-27 | Mitsuma Miyoshi | Powdered food and drink |
| JPS5931710A (en) * | 1982-08-17 | 1984-02-20 | Masaki Takahara | Drinking solution for supplying calcium |
-
1985
- 1985-01-29 JP JP1360885A patent/JPS61172822A/en active Granted
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS5148467A (en) * | 1974-10-23 | 1976-04-26 | Kyoko Ootsu | |
| JPS5585385A (en) * | 1978-12-22 | 1980-06-27 | Mitsuma Miyoshi | Powdered food and drink |
| JPS5931710A (en) * | 1982-08-17 | 1984-02-20 | Masaki Takahara | Drinking solution for supplying calcium |
Also Published As
| Publication number | Publication date |
|---|---|
| JPS61172822A (en) | 1986-08-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Eliseeva et al. | Vitamin C (ascorbic acid)–description, benefits and where it is found | |
| TW200927126A (en) | Composition comprising sesamin component and vitamin b1 component | |
| EP0040654A2 (en) | Electrolyte drink concentrate | |
| GB2037565A (en) | Electrolyte drink | |
| CN105614860A (en) | Probiotic compound oligopeptide nutritional supplement capable of lowering uric acid | |
| KR20110013685A (en) | A functional beverage comprising deep sea water, extract of fermented black ginger and extract of jujubae fructus as main ingredients | |
| JPH01108958A (en) | Magnesium additive for nutritive substance, food and drug | |
| US4497798A (en) | Appetite suppressant | |
| JPH09183732A (en) | Potassium dominant non-solution pill and health promotion using the pill | |
| RU2472354C1 (en) | Biologically active food additive "selenium-iodine-elastin" | |
| JP2008237058A (en) | Dietary supplement | |
| JPH0113691B2 (en) | ||
| JPH0113692B2 (en) | ||
| EP1660103B1 (en) | Enhancement of magnesium uptake in mammals | |
| WO2001022943A1 (en) | A slow release pharmaceutical composition comprising a magnesium oxychloride cement | |
| GB2292522A (en) | Multi-vitamin preparation for treatment of the immune system | |
| Newnham | How boron is being used in medical practice | |
| JPH0925236A (en) | Alkaline electrolytic water containing zinc | |
| JPH02242655A (en) | Meterial reducing adverse reaction of kitchen salt | |
| KR20170103380A (en) | Composition For Improving Skin Constitution Between Race | |
| JP2564648B2 (en) | Liquid food additive containing high concentration of ionized calcium, method for producing the same, and processed food to which the food additive is added | |
| EP1599198B1 (en) | Potassium taurate bicarbonate and ascorbate complexes | |
| JPS59203481A (en) | Health carbonated drinking water | |
| PT1093337E (en) | Food supplements comprising lipoic acid and creatine and methods for their use | |
| RU2205648C1 (en) | "calcisan" composition for prophylaxis and maintenance therapy in case of gastro-intestinal diseases |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EXPY | Cancellation because of completion of term |